Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.45 |
| ▸ | TMIGD3 | P0DMS9 | 4/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.39 |
| ▸ | PDE8B | O95263 | 2/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30731519 | 1.00 | ADORA2A (0.45) | ADORA2AADORA2BADORA1TMIGD3TLR7 | |
| SCHEMBL2199492 | 0.86 | TLR7 (0.38) | ADORA2AADORA2BADORA1TMIGD3TLR7 | |
| SCHEMBL4136764 | 0.86 | ALDH1A1 (0.42) | ADORA2AADORA2BADORA1TMIGD3PDE8B | |
| SCHEMBL3322870 | 0.86 | ADORA2A (0.43) | ADORA2AADORA2BADORA1TMIGD3PDE8B | |
| SCHEMBL16882930 | 0.81 | ADORA2A (0.35) | ADORA2AADORA2BADORA1TMIGD3PDE8B | |
| SCHEMBL3378114 | 0.81 | ADORA2A (0.35) | ADORA2AADORA2BADORA1TMIGD3PDE8B | |
| SCHEMBL1848717 | 0.81 | ADORA2A (0.35) | ADORA2AADORA2BADORA1TMIGD3PDE8B | |
| SCHEMBL12157544 | 0.80 | TP53 (0.49) | ADORA2AADORA2BADORA1TMIGD3FLT3 | |
| SCHEMBL567681 | 0.79 | TLR7 (0.48) | ADORA2AADORA2BTLR7 | |
| SCHEMBL29809145 | 0.79 | TLR7 (0.48) | ADORA2AADORA2BTLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024020684-A1 | IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOF | ZYMEWORKS BC INC. (CA) | 2024-02-01 | — | — | WO | disclosed |
| US-20120283438-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120283438-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120283438-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-11-08 | — | — | US | disclosed |
| US-20110269781-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269781-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-11-03 | — | — | US | disclosed |
| US-7977344-B2 | Compounds | GLAXOSMITHKLINE LLC (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977344-B2 | Compounds | GLAXOSMITHKLINE LLC (US) | 2011-07-12 | — | — | US | disclosed |
| EP-2125792-B1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | GLAXOSMITHKLINE LLC (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20100120799-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120799-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120799-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-20090131458-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131458-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131458-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283438-A1 | COMPOUNDS | LTC4S, LTB4R2, LTB4R | ADORA2A 907/4885ADORA2B 494/4885ADORA1 694/4885 |
| US-20090131458-A1 | Compounds | LTC4S, LTB4R2, LTB4R | ADORA2A 907/4885ADORA2B 494/4885ADORA1 694/4885 |
| US-20100120799-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | LTC4S, STING1, LTB4R2 | ADORA2A 54/4885ADORA2B 33/4885ADORA1 39/4885 |
| US-20110269781-A1 | COMPOUNDS | LTC4S, LTB4R2, LTB4R | ADORA2A 907/4885ADORA2B 494/4885ADORA1 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.